|
|
A Genetic Toolbox for the Identification and Interrogation of Tumor Cells of Origin, Propagation, and Recurrence From Patient-derived Oncogenic Drivers
|
5R33CA202900-02
|
$412,553
|
$412,553
|
BREUNIG, JOSHUA
|
CEDARS-SINAI MEDICAL CENTER
|
|
|
A microRNA mediating vascular directed fibrinolysis and tumor progression
|
1F31CA213793-01
|
|
$0
|
MCCANN, JAMES
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
A microRNA mediating vascular directed fibrinolysis and tumor progression
|
7F31CA213793-02
|
$33,314
|
$33,314
|
MCCANN, JAMES
|
UNIVERSITY OF VIRGINIA
|
|
|
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer
|
5R01CA175318-03
|
$354,563
|
$354,563
|
HATEFI, ARASH
|
RUTGERS, THE STATE UNIV OF N.J.
|
|
|
A New Ovarian Cancer Mouse Model Based on Nanoparticle Gene Delivery
|
1R03CA216127-01
|
$77,000
|
$77,000
|
YANG, YANG
|
YALE UNIVERSITY
|
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-03
|
$473,915
|
$236,958
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
|
1R01CA217179-01
|
$566,814
|
$566,814
|
MARKERT, JAMES
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-03
|
$1
|
$1
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Adenoviral delivery of protein-based therapeutics to the tumor microenvironment
|
5F32CA189372-03
|
$48,216
|
$48,216
|
SMITH, SHEENA
|
UNIVERSITY OF ZURICH
|
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,629,581
|
$651,832
|
Rosenberg, Steven
|
CCR (NCI)
|
|
|
Adoptive T cell Therapy for Pediatric Leukemia
|
ZIA BC 011565
|
$776,399
|
$232,920
|
Fry, Terry
|
CCR (NCI)
|
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011415
|
$13,582
|
$13,582
|
Kochenderfer, James
|
CCR (NCI)
|
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
1R44CA221539-01
|
$1,206,955
|
$1,206,955
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
|
Biology and Transplantation of the Hematopoietic Stem Cell
|
5P01CA065493-23
|
$1,914,865
|
$421,270
|
WAGNER, JOHN
|
UNIVERSITY OF MINNESOTA
|
|
|
BMP4 Engineered Mesenchymal Stem Cell Therapy for Glioblastoma
|
3R01CA183827-03S1
|
$133,280
|
$133,280
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
|
BMP4 Engineered Mesenchymal Stem Cell Therapy for Glioblastoma
|
7R01CA183827-03
|
$322,194
|
$322,194
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
|
Building on the success of the adoptive immunotherapy of cancer
|
ZIA BC 010763
|
$1,562,883
|
$390,721
|
Restifo, Nicholas
|
CCR (NCI)
|
|
|
Cancer Prevention and Treatment by Activation of a Brain-Adipocyte Axis
|
5R01CA166590-05
|
$319,550
|
$159,775
|
CAO, LEI
|
OHIO STATE UNIVERSITY
|
|
|
Cancer-targeted local pulmonary immunotherapy with PD-L1 inhibitory peptide secretory genes for the treatment of lung cancer
|
1R15CA219919-01
|
$380,000
|
$380,000
|
TAMURA, MASAAKI
|
KANSAS STATE UNIVERSITY
|
|
|
Career Development in Pediatric and Medical Oncology
|
5K12CA076930-17
|
$701,719
|
$231,567
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Cell Production Core Facility
|
ZIC BC 011569
|
$933,290
|
$466,645
|
Somerville, Robert
|
CCR (NCI)
|
|
|
Cellular biofactories for therapeutic protein synthesis in tumor microenvironment
|
5R21CA193064-04
|
$240,357
|
$240,357
|
BHATNAGAR, PARIJAT
|
SRI INTERNATIONAL
|
|
|
Clinical production of viral vectors for cancer gene therapy
|
ZIC BC 010989
|
$556,461
|
$556,461
|
Feldman, Steven
|
CCR (NCI)
|
|
|
Clinical Scholars Biomedical Research Training Program
|
2T32CA009512-29A1
|
$302,877
|
$60,575
|
SPRIGGS, DAVID
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Colorectal Cancer: Characterization of a new Cre-LoxP Model
|
1R03CA216160-01
|
$60,790
|
$30,395
|
KHARE, SHARAD
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
|
|
Combination Gene Therapy and Th1-Th2 Therapy
|
ZIA BC 011219
|
$272,402
|
$136,201
|
Fowler, Daniel
|
CCR (NCI)
|
|
|
Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy
|
5R01CA194064-03
|
$283,650
|
$141,825
|
MING, XIN
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
|
Common hTERT Promoter Mutations Represent a Novel Therapeutic Target
|
5R21CA191663-02
|
$200,970
|
$200,970
|
MILLER, DONALD
|
UNIVERSITY OF LOUISVILLE
|
|
|
CRLF2 signaling in B-cell acute lymphoblastic leukemia
|
5R01CA151898-07
|
$392,969
|
$196,485
|
WEINSTOCK, DAVID
|
DANA-FARBER CANCER INST
|
|
|
Design of Oncolytic Adenovirus Conjugated with Novel Polymer for Cancer Treatment
|
5R01CA177932-05
|
$309,175
|
$309,175
|
KIM, SUNG WAN
|
UNIVERSITY OF UTAH
|
|
|
Developing a Novel System for Cancer Therapy: Tumor-Targeted Inhibition of Oncogenic MicroRNAs
|
5F30CA196020-03
|
$28,344
|
$14,172
|
SVORONOS, ALEXANDER
|
YALE UNIVERSITY
|
|
|
Development of fully-human anti-CD30 chimeric antigen receptors
|
ZIA BC 011660
|
$67,909
|
$67,909
|
Kochenderfer, James
|
CCR (NCI)
|
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-13
|
$2,300,000
|
$276,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
DICER1 and the Pleuropulmonary Blastoma Family Cancer Syndrome
|
5R01CA143167-07
|
$407,577
|
$407,577
|
HILL, DANA
|
CHILDREN'S RESEARCH INSTITUTE
|
|
|
Direct coregulation of Notch1 by Zmiz1 in T-cell leukemia
|
5R01CA196604-03
|
$354,563
|
$177,282
|
CHIANG, MARK
|
UNIVERSITY OF MICHIGAN
|
|
|
Disrupting tumor/bone malignant interactions with multifunctional cytokine sonodelivery
|
5R01CA196947-02
|
$350,644
|
$350,644
|
FIGUEIREDO, MARXA
|
PURDUE UNIVERSITY
|
|
|
DNA-specific pattern recognition receptor activation following DNA electroporation
|
5R01CA196796-02
|
$316,169
|
$158,085
|
HELLER, LOREE
|
OLD DOMINION UNIVERSITY
|
|
|
Duke SPORE in Brain Cancer
|
5P50CA190991-04
|
$2,298,025
|
$91,921
|
SAMPSON, JOHN
|
DUKE UNIVERSITY
|
|
|
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies
|
5R00CA181491-04
|
$250,586
|
$125,293
|
BALKO, JUSTIN
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
|
Efficient Delivery of Plasmid DNA to Achieve Appropriate Transgene Expression
|
5R01CA186730-03
|
$353,892
|
$353,892
|
HELLER, RICHARD
|
OLD DOMINION UNIVERSITY
|
|
|
Elucidating the role of microRNAs in the initiation of multiple myeloma
|
5R00CA172292-05
|
$248,999
|
$74,700
|
ZHAO, JIANJUN
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
|
Engineering Viruses for Cancer Therapy
|
1R03CA216179-01
|
$68,748
|
$68,748
|
PENG, CHING-AN
|
UNIVERSITY OF IDAHO
|
|
|
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells
|
3R01CA181598-04S1
|
$100,813
|
$50,407
|
GILBOA, ELI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
|
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells
|
5R01CA181598-04
|
$318,513
|
$159,257
|
GILBOA, ELI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
|
Enhancing miRNA Therapeutics through Combinatorial Targeting and Vehicle Free Delivery
|
1R01CA205420-01A1
|
$349,399
|
$174,700
|
KASINSKI, ANDREA
|
PURDUE UNIVERSITY
|
|
|
ENHANCING T CELL THERAPY OF CANCER
|
5P01CA094237-15
|
$1,932,287
|
$966,144
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Enhancing viral oncolysis with vasculostatin gene delivery
|
5R01CA150153-07
|
$64,775
|
$64,775
|
KAUR, BALVEEN
|
OHIO STATE UNIVERSITY
|
|
|
Enhancing viral oncolysis with vasculostatin gene delivery
|
7R01CA150153-08
|
$336,268
|
$336,268
|
KAUR, BALVEEN
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
|
Exploring the therapeutic potential and pathogenic contribution of MTAP deletion in Glioblastoma
|
1F30CA206336-01A1
|
$35,090
|
$35,090
|
HANSEN, LANDON
|
DUKE UNIVERSITY
|
|
|
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas
|
2P01CA069246-20
|
$1,387,951
|
$610,698
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Total relevant funding to Gene Therapy for this search: $35,689,813
|
